Abstract
Introduction

42
Urinary tract infections (UTIs) are common bacterial infections in dogs, occurring in 43 approximately 14% of dogs in their lifetimes with a variable age at onset [1] . Escherichia coli is 44 the most common infectious bacteria, although various gram-negative and gram-positive 45 bacteria can cause UTIs in dogs [2, 3] . 46 The prevalence of extended-spectrum β-lactamase (ESBL)-producing bacteria is of great concern worldwide in companion animals with UTIs [4, 5] . Although ESBLs are usually 48 involved in resistance to oxyimino-cephalosporins, penicillins, and narrow-spectrum 49 cephalosporins, ESBL-producing bacteria are often resistant to other classes of antimicrobials 50 [6]. These multidrug-resistant phenotypes of ESBL-producing bacteria have major implications 51 in the selection of adequate empirical therapy regimens [6] . 52 We previously reported high in vitro efficacy of several antimicrobials against ESBL-53 producing E. coli (ESBL-EC) isolates from companion animals [7] . Of these antimicrobials, 54 faropenem is representative of the penem class and exhibits stability to hydrolysis by ESBLs 55 [8, 9] ; additionally, it is highly safe in dogs [10, 11] . These findings indicate that faropenem may 56 be a promising candidate antimicrobial for canine UTIs with ESBL-producing bacteria. 57 However, the urinary pharmacokinetic/pharmacodynamic profile, which is essential for 
Results
144
Safety and laboratory test results
145
No adverse effects were observed in any dogs during the test period. The results of the physical 146 examination, complete blood count, and biochemical blood test displayed no clinically relevant 147 changes.
148
Urine concentration and urinary excretion 149 The LC-MS assay showed a lower limit of quantitation at 10 ng/mL for faropenem in dog urine.
150
The urine volume, urinary concentration, and cumulative excretion are shown in 
UBTs and AUBTs
164
The temporal changes in the median UBTs for each strain are shown in Figure 1 . In all tested 165 ESBL-EC strains, the median UBTs of faropenem peaked at 0 to 4 h and then significantly 166 decreased at 4 to 8 h and/or 8 to 12 h (P < 0.05). 
MBCs and MUBCs
184
The MBCs ranged from 1 to 16 µg/mL (one to two times the corresponding MIC for each 185 strain), whereas the median MUBCs ranged from 0.98 to 11.94 µg/mL ( Table 1 ). The ratios of 186 the median MUBC to the corresponding MBC ranged from 0.64 to 3.62.
188
Discussion
189
Although faropenem shows excellent in vitro antimicrobial activity against ESBL-producing 190 bacteria [7] , its efficacy for canine UTIs with these bacteria has not been previously assessed.
191
To our knowledge, this is the first report to investigate the urinary pharmacokinetics and 192 pharmacodynamics of faropenem in dogs.
193
The present study demonstrated that in dogs, approximately one-third of the dose of 194 faropenem is excreted in urine 12 h after oral administration. This urinary excretion of 195 faropenem in dogs is higher than that in humans: urinary excretion of the drug after oral 196 administration at a 300-mg dose in human patients was merely 14% to 20% [9] . These findings imply that this drug is more suitable for treatment of UTIs in dogs than in humans, possibly 198 because of the differences in absorption, distribution, metabolism, and elimination between 199 dogs and humans.
200
In this study, we also found an extremely low concentration of faropenem in dog urine at 201 8 to 12 h, and the cumulative excretion remained almost unchanged from 4 to 8 h to 8 to 12 h. 
